<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Investigational therapies for treating symptoms of lower extremity peripheral artery disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Investigational therapies for treating symptoms of lower extremity peripheral artery disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Investigational therapies for treating symptoms of lower extremity peripheral artery disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Connie N Hess, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc P Bonaca, MD, MPH, FAHA, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis L Clement, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Creager, MD, FAHA, FACC, MSVM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H50940670"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pharmacologic therapies under investigation that may become useful for patients with peripheral artery disease (PAD) to improve symptoms of claudication, with the added benefit of avoiding the need for revascularization, to promote healing of ischemic ulcers, or to alter perception of ischemic pain in patients who are poor candidates or who have failed revascularization attempts are reviewed here. The clinical use of these agents is <strong>not</strong> yet recommended.</p><p>For patients with claudication, evidence of benefit of pharmacologic agents for improving symptoms is available only for <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> and naftidrofuryl (not available in the United States) [<a href="#rid1">1-4</a>]. Statin therapy for PAD is associated with a reduction in limb events, including claudication, lower extremity revascularization, and critical limb ischemia, but evidence for the use of statins to improve PAD symptoms is not definitive [<a href="#rid3">3</a>]. Recommendations for these and other potentially beneficial pharmacologic agents are discussed separately. (See  <a class="medical medical_review" href="/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Beneficial'</a> and  <a class="medical medical_review" href="/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Benefit not firmly established'</a>.) </p><p>The best therapeutic option for patients with chronic limb-threatening ischemia manifesting as rest pain, ischemic ulceration, or gangrene is revascularization (percutaneous or surgical). However, many patients are poor candidates for revascularization due to severe medical comorbidities. (See  <a class="medical medical_review" href="/d/html/8215.html" rel="external">"Management of chronic limb-threatening ischemia"</a>.)</p><p>Pharmacologic therapy aimed at reducing the risk for future cardiovascular events in patients with PAD, and that may also limit progression of disease, are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p class="headingAnchor" id="H919447633"><span class="h1">HOME EXERCISE PROGRAMS</span><span class="headingEndMark"> — </span>The benefits of supervised exercise therapy are well documented, and the data on this therapy have led to approval in the United States by the Centers for Medicare &amp; Medicaid Services (CMS) for reimbursement. However, these programs are not commonly available and may not be an option for many patients. As a result, there is interest in developing more efficient ways to deploy home-based exercise programs. (See  <a class="medical medical_review" href="/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Supervised versus unsupervised exercise'</a>.)</p><p>Randomized trials comparing exercise regimens include a large study of 180 patients with claudication who were randomized into a 12-week exercise program [<a href="#rid5">5</a>]. Groups received supervised exercise, home-based exercise, or control. The results demonstrated improvement in treadmill exercise performance in both exercise groups with a greater improvement in six-minute walk distance in the home-based group compared with control [<a href="#rid5">5</a>]. A meta-analysis of 11 trials of structured home exercise that included 807 patients showed improvement in treadmill and six-minute walk test endpoints compared with controls not receiving an exercise program [<a href="#rid6">6</a>]. By contrast, a randomized trial of home-based exercise intervention that included a wearable activity monitor and telephone coaching did not improve walking performance more than usual care [<a href="#rid7">7</a>]. Another study evaluated a Group Mediated Cognitive Behavioral (GMCB) intervention, which was a behavioral component to enhance adherence to home-based walking exercise [<a href="#rid8">8</a>]. The combination of the behavioral intervention with home exercise was more effective in improving exercise performance than an attention control group [<a href="#rid9">9</a>]. </p><p class="headingAnchor" id="H50945854"><span class="h1">PHARMACOLOGIC AGENTS</span><span class="headingEndMark"> — </span>The pathophysiology of symptoms associated with ischemia is complex and provides multiple potential targets for novel drug therapies [<a href="#rid10">10,11</a>]. Potential future pharmacologic therapies that remain to be proven beneficial for the treatment of symptoms associated with lower extremity PAD are presented below. These therapies may be targeted either to symptoms of claudication or to more severe manifestations of ischemia, such as ischemic rest pain, ulceration, or gangrene. </p><p class="headingAnchor" id="H491227958"><span class="h2">Antiinflammatory therapies</span><span class="headingEndMark"> — </span>Vascular inflammation has been associated with progression of atherosclerosis [<a href="#rid12">12</a>], and major adverse cardiovascular events [<a href="#rid13">13,14</a>]. Treatment of 38 patients with PAD for up to 12 months with the interleukin-1 beta antagonist <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> versus placebo did not alter plaque progression in the superficial femoral artery but did improve maximum and pain-free walking distances as early as three months [<a href="#rid15">15</a>]. Whether these findings are related to improved skeletal muscle perfusion and/or endothelial function as a result of reduced inflammation warrants additional investigation. </p><p>Closely related to inflammation is the process of efferocytosis, or the clearing of apoptotic cells by phagocytes. Impaired efferocytosis has been implicated in atherogenesis, and expansion of the necrotic core in atherosclerotic plaques may promote plaque vulnerability [<a href="#rid16">16</a>]. The antiefferocytic molecule CD47 has been demonstrated to be upregulated in atherosclerotic plaques [<a href="#rid17">17</a>]. Treatment of nine patients with lymphoma with the humanized anti-CD47 antibody magrolimab was shown to reduce vascular inflammation as measured by <sup>18</sup>F-fluorodeoxyglucose uptake in the carotid artery [<a href="#rid18">18</a>]. The potential utility of this therapy in patients with atherosclerotic cardiovascular disease, including PAD, has yet to be examined.</p><p class="headingAnchor" id="H222166545"><span class="h2">Antioxidants</span><span class="headingEndMark"> — </span>These treatments inhibit oxidation of other molecules, particularly in key mitochondrial metabolic pathways. A number of antioxidant therapies have been evaluated in patients with PAD; however, studies on walking performance have yielded mixed results, with positive studies showing only a modest beneficial effect, or no effect [<a href="#rid10">10,19-23</a>]. Antioxidants have also been evaluated for primary and secondary prevention of cardiovascular disease. (See  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Antioxidants'</a>.)</p><p class="headingAnchor" id="H415061735"><span class="h2">Polyphenols</span><span class="headingEndMark"> — </span>Polyphenols are antioxidant phytochemicals found in plant-based foods. </p><p>Cocoa is a concentrated source of flavanols, which are a part of the polyphenol subgroup called flavonoids [<a href="#rid24">24,25</a>]. The subclass of flavanols found in cocoa are epicatechin and catechin derivatives. Cocoa can cause arterial dilatation by reducing oxidative stress and by increasing production of nitric oxide. Dark chocolate, in particular, can enhance arterial dilatation by lowering activation of NOX2, a catalytic subunit of NADPH oxidase. Despite these attractive mechanisms, a single consumption of dark chocolate had no effect on endothelial or microvascular function in patients with symptomatic PAD [<a href="#rid26">26</a>]. However, in a study of 20 PAD patients, dark, but not milk, chocolate improved maximal walking distance and maximal walking time [<a href="#rid27">27</a>]. The COCOA-PAD trial was a placebo-controlled pilot study of daily cocoa intake in PAD patients who were at least 60 years of age that showed improved six-minute walk distance at six-month follow-up as well as improved mitochondrial cytochrome c oxidase activity, increased capillary density, and improved calf muscle perfusion in patients receiving cocoa versus placebo [<a href="#rid28">28</a>]. </p><p>There has been suggestion that Annurca apple polyphenols, which contain the same catechin-derived compounds found in cocoa, may provide benefit for patients with intermittent claudication. In a study of 180 patients with claudication, treatment for 24 weeks with Annurca apple extract significantly improved maximal walking distance, ankle-brachial index, and acceleration time compared with placebo [<a href="#rid29">29</a>]. However, these results should be considered preliminary and have not yet been replicated in other studies. </p><p class="headingAnchor" id="H3419120116"><span class="h2">Endothelial-modulating agents</span><span class="headingEndMark"> — </span>The endothelium regulates vascular tone, inhibits platelet aggregation and leucocyte attraction, and promotes angiogenesis through the release of vasoactive substances, including nitric oxide [<a href="#rid30">30,31</a>]. Nitric oxide (NO) is produced from the substrate L-arginine by three forms of nitric oxide synthase (NOS), with the majority from endothelial nitric oxide synthase using tetrahydrobiopterin (BH4) as a cofactor. Plasma nitrite can be reduced to NO under low oxygen conditions, such as ischemia, and thus may serve as a physiologic store of NO  (<a class="graphic graphic_figure graphicRef118395" href="/d/graphic/118395.html" rel="external">figure 1</a>) [<a href="#rid32">32</a>]. Patients with PAD have endothelial dysfunction and reduced NO bioavailability, forming the basis for investigation into strategies to increase NO activity in PAD patients.</p><p class="headingAnchor" id="H1668678077"><span class="h2">Dietary nitrates</span><span class="headingEndMark"> — </span>Oral consumption of inorganic nitrate can increase plasma nitrite levels [<a href="#rid33">33-35</a>]. Although the majority of inorganic nitrate is excreted in the urine, up to 25 percent is retained and stored in salivary glands. When saliva is secreted, oral bacteria reduce the nitrate to nitrite, which is swallowed and reabsorbed back into circulation. Dietary sources with high concentrations of nitrate include leafy green vegetables and beetroot. In healthy and athlete populations, dietary nitrate supplementation has shown benefit, including improved time trial performance, increased time to exhaustion, and decreased oxygen cost of exercise [<a href="#rid36">36-38</a>]. No impact of dietary nitrate has been found for improving power output, time trial time, or submaximal exercise efficiency among healthy subjects [<a href="#rid39">39-42</a>]. </p><p>Exaggerated hemodynamic responses to physiologic stressors may be associated with hypertension and major adverse cardiac events (MACE) in aging populations [<a href="#rid43">43,44</a>]. In a placebo-controlled trial of 21 patients with PAD, dietary supplementation with sodium nitrate reduced exaggerated systolic blood pressure responses to sympatho-excitation using a cold pressor test [<a href="#rid45">45</a>]. Whether sodium nitrate supplementation is a novel strategy to reduce risk of hypertension and MACE in patients with PAD needs further investigation. </p><p>With respect to functional outcomes, in an early placebo-controlled trial, supplementation with beetroot juice increased plasma nitrite levels fivefold and increased claudication onset time and peak walk times during treadmill walking by 18 and 17 percent, respectively [<a href="#rid34">34</a>]. A placebo-controlled study of beetroot juice in conjunction with supervised exercise training in patients with intermittent claudication showed improvement in claudication onset time and six-minute walk distance with beetroot juice plus exercise compared with exercise alone [<a href="#rid46">46,47</a>]. The effect of beetroot juice on coronary blood flow and walking performance in PAD is also under study in the ongoing HeartBeet trial (NCT02553733), and a trial examining beetroot juice on endothelial function, walking capacity, leg function, and thermoregulation in PAD patients has completed enrollment but is still ongoing (NCT03506646). </p><p class="headingAnchor" id="H4272787306"><span class="h3">Sodium nitrite</span><span class="headingEndMark"> — </span>Nitrite is a first-order metabolite of nitric oxide. Following exercise, nitrite stores decrease in patients with PAD compared with healthy individuals [<a href="#rid48">48,49</a>]. Animal studies have suggested that <a class="drug drug_general" data-topicid="85782" href="/d/drug information/85782.html" rel="external">sodium nitrite</a> can promote new blood vessel growth, speed up wound healing, and prevent tissue necrosis. Studies showing that nitrite therapy may protect against ischemia-related heart and brain injury in cardiac arrest survivors have led to interest in using sodium nitrate to treat lower extremity ischemia [<a href="#rid50">50,51</a>]. </p><p>In a safety and efficacy trial, 55 patients with PAD, predominantly with diabetes, were treated over a period of 10 weeks with either placebo (n = 18) or <a class="drug drug_general" data-topicid="85782" href="/d/drug information/85782.html" rel="external">sodium nitrite</a> twice daily, 40 mg (n = 19) or 80 mg (n = 18) [<a href="#rid49">49</a>]. The primary endpoint of endothelium-dependent, flow-mediated dilatation (FMD) was worse in the placebo and 40 mg groups (but not significantly different) and stable in the 80 mg group. Patients with diabetes receiving 80 mg had significantly higher FMD compared with the placebo and 40 mg groups. There were no significant changes in six-minute walk test or quality of life parameters over time compared with placebo. The most common side effects attributed to sodium nitrite were a composite of headache and dizziness occurring in 21 percent with the 40 mg dose and 44 percent with the 80 mg dose. There was no clinically significant elevation of methemoglobin [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H974954074"><span class="h3">Tetrahydrobiopterin (BH4)</span><span class="headingEndMark"> — </span>BH4 is a cofactor for the production of nitric oxide by endothelial nitric oxide synthase. The effect of oral supplementation of BH4 versus placebo on peak walking time in patients with symptomatic PAD has been investigated in a phase 2 study (NCT00403494), but results have not yet been published. </p><p class="headingAnchor" id="H371741682"><span class="h3">L-arginine</span><span class="headingEndMark"> — </span>Previous studies have reported mixed results regarding improved vascular function after supplementation with L-arginine in patients with cardiovascular disease [<a href="#rid53">53-55</a>]. In PAD, the effect of L-arginine on endothelial function was examined in the LargPAD trial, a phase 2A evaluation of catheter-directed L-arginine infusion into atherosclerotic superficial femoral arteries in 22 PAD patients undergoing lower extremity angiography. L-arginine infusion increased nitric oxide bioactivity and improved endothelial function, as measured by intravascular ultrasound and Doppler flow wire during acetylcholine-induced endothelium-dependent arterial relaxation [<a href="#rid56">56</a>]. </p><p>In the Nitric Oxide in Peripheral Arterial Insufficiency (NO-PAIN) study, 133 subjects with intermittent claudication were randomly assigned oral L-arginine (3 g/day) or placebo for six months [<a href="#rid57">57</a>]. While L-arginine supplementation significantly increased plasma L-arginine levels, measures of NO availability were reduced or not improved compared with placebo. The functional endpoints of absolute claudication distance and initial claudication distance were numerically less improved, and flow-mediated dilatation was significantly reduced with L-arginine treatment compared with placebo. Thus, this treatment cannot be recommended at this time.</p><p class="headingAnchor" id="H1741902847"><span class="h3">L-citrulline</span><span class="headingEndMark"> — </span>Only approximately 1 percent of oral L-arginine supplementation is available for nitric oxide production, with the rest metabolized by the body [<a href="#rid55">55</a>]. Consequently, L-citrulline, which is a precursor of L-arginine, is also under consideration as a possible therapy for PAD. A placebo-controlled double-blind crossover trial in 25 older adults demonstrated increased femoral blood flow and vascular conductance during lower-limb exercise in older men [<a href="#rid58">58</a>]. Another placebo-controlled double-blind crossover study of oral L-citrulline examining vascular function measured by flow-mediated dilation and treadmill performance was completed, but results have not been published (NCT02521220). </p><p class="headingAnchor" id="H135435783"><span class="h2">Phosphodiesterase inhibitors</span><span class="headingEndMark"> — </span>Phosphodiesterase (PDE) inhibitors cause vasodilation through a nitric oxide-cyclic guanosine monophosphate pathway, and the drugs have metabolic effects on triglyceride metabolism. <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">Cilostazol</a> is a PDE inhibitor with selective activity for the type III isozyme. Cilostazol has proven benefit for the treatment of claudication with Food and Drug Administration (FDA) approval for treatment of symptomatic PAD, with a black box warning to avoid its use in patients with heart failure. (See  <a class="medical medical_review" href="/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Cilostazol'</a>.) </p><p>Other drugs in this class are no longer under investigation despite positive results for other drugs in this class such as NM-702 and K-134 [<a href="#rid59">59,60</a>]. </p><p class="headingAnchor" id="H221325223"><span class="h2">Prostanoids</span><span class="headingEndMark"> — </span>Prostaglandin, prostacyclin, and their analogs improve blood flow through direct vasodilation, antiplatelet, and other rheologic effects and have anti-inflammatory effects as well [<a href="#rid61">61,62</a>]. While some of these drugs remain under investigation, they have not been approved for treating the symptoms of PAD in the United States. </p><p>Agents previously investigated for the treatment of PAD include prostaglandin E1 (<a class="drug drug_general" data-topicid="8459" href="/d/drug information/8459.html" rel="external">alprostadil</a>) [<a href="#rid61">61,63-66</a>], the prostaglandin analog ecraprost [<a href="#rid67">67,68</a>], the prostacyclin <a class="drug drug_general" data-topicid="9411" href="/d/drug information/9411.html" rel="external">epoprostenol</a> (PGI2), as well as the prostacyclin analogs <a class="drug drug_general" data-topicid="8895" href="/d/drug information/8895.html" rel="external">iloprost</a> (inhalation, intravenous [IV] not available in the United States), beraprost (oral, not available in the United States) [<a href="#rid69">69</a>], taprostene, and <a class="drug drug_general" data-topicid="10207" href="/d/drug information/10207.html" rel="external">treprostinil</a> (inhalation, oral, subcutaneous, IV) [<a href="#rid70">70-72</a>]. Prostaglandin E1 (PGE1) and epoprostenol (PGI2) are structurally unstable. Their stable analogs have a longer duration of action and a more specific effect (in general) than their endogenous equivalents. </p><p class="bulletIndent1"><span class="glyph">●</span>Claudication – A systematic review and meta-analysis (Cochrane) identified 18 trials [<a href="#rid61">61</a>]. Four trials that compared PGE1 with placebo found significant improvements in treadmill exercise performance with PGE1 but not PGI2. However, the authors noted that the quality of individual trials was variable and results often unclear due to insufficient reporting information; the majority of trials did not report standard deviations for the primary outcomes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic limb-threatening ischemia – In a systematic review and meta-analysis (Cochrane) [<a href="#rid73">73</a>], 15 trials compared various preparations of prostacyclin analogues with placebo. No differences were seen for cardiovascular mortality or overall amputation risk (minor and major) for patients receiving prostanoids compared with placebo. However, prostanoids may reduce rest pain (risk ratio [RR] 1.30, 95% CI 1.06-1.59) and improve ulcer healing (RR 1.24, 95% CI 1.04-1.48) compared with placebo. Adverse events were more frequent with prostanoids. </p><p></p><p class="headingAnchor" id="H200382509"><span class="h2">Ramipril</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9851" href="/d/drug information/9851.html" rel="external">Ramipril</a> is an angiotensin-converting enzyme (ACE) inhibitor. Ramipril has been associated with an increase in the biomarkers of angiogenesis/arteriogenesis and reduction in the markers of thrombosis, inflammation, and leukocyte adhesion. One small trial randomly assigned 33 subjects ramipril or placebo. After 24 weeks, ramipril improved maximum treadmill walking distance by an adjusted mean difference of 131 meters and mean pain-free distance by 122 meters [<a href="#rid74">74</a>]. Another randomized trial of 212 patients demonstrated no clinical benefit for patients treated with ramipril (study was subsequently retracted) [<a href="#rid75">75</a>]. In a systemic review and metaanalysis of four randomized clinical trials, there was no evidence for improvement of treadmill walking distance or ankle-brachial index (ABI) in patients with symptomatic PAD [<a href="#rid76">76</a>]. However, a phase 4 clinical trial investigating use of ramipril for the treatment of claudication is ongoing (NCT02842424). </p><p class="headingAnchor" id="H3948097564"><span class="h2">Ranolazine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">Ranolazine</a> is approved for the treatment of angina pectoris, but there is little evidence for its use in treating PAD. In a small trial of 45 patients with intermittent claudication, patients were randomly assigned to ranolazine 1000 mg twice daily or placebo for four weeks. Ranolazine did not improve peak walking performance, but pain-free walking time was improved relative to baseline walking time, suggesting the possibility of a treatment effect. A follow-up study of supervised exercise and ranolazine compared with placebo enrolled 29 patients (NCT00914316) [<a href="#rid77">77</a>]. The study was terminated early in 2013 due to challenges in recruitment and retention, with unpublished results. </p><p class="headingAnchor" id="H2393759033"><span class="h2">Glucagon-like peptide-1 (GLP-1) analogues</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">Semaglutide</a> and <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a> are GLP-1 analogues. In patients with type 2 diabetes mellitus at high cardiovascular risk, semaglutide significantly reduced the rate of major adverse cardiovascular events (MACE) compared with placebo in the SUSTAIN 6 trial [<a href="#rid78">78</a>]. Data presented from subgroup analyses from LEADER (placebo-controlled trial of liraglutide) and SUSTAIN 6 have demonstrated reductions in cardiovascular events associated with GLP-1 analogues in patients with and without PAD [<a href="#rid79">79</a>]. With respect to limb-specific outcomes, treatment with liraglutide in patients with diabetes at high cardiovascular risk was associated with a significant reduction in diabetic foot ulcer-related amputations compared with placebo [<a href="#rid80">80</a>]. The STRIDE trial of 800 participants randomized to semaglutide versus placebo is underway to determine whether semaglutide has any benefits for walking ability in those with diabetes and PAD (NCT04560998). </p><p class="headingAnchor" id="H1877818924"><span class="h2">SNF472</span><span class="headingEndMark"> — </span>Vascular calcification involves the deposition of calcium phosphate hydroxyapatite crystals into the arterial intima or media. Medial calcification, including smaller subcutaneous arteries, has been observed in approximately three-quarters of patients with PAD. Advanced chronic kidney disease is a common comorbid condition among patients with PAD and is associated with increased risk for cardiovascular death compared with the general population [<a href="#rid81">81</a>]. Some of this risk is attributed to higher prevalence of traditional cardiovascular risk factors, such as diabetes mellitus and hypertension, in patients with chronic kidney disease. However, vascular calcification related to accelerated atherosclerosis and deranged mineral metabolism leading to arteriosclerosis is one of the strongest predictors of cardiovascular risk and has been associated with cardiovascular morbidity and mortality, as well as all-cause mortality in renal patients [<a href="#rid82">82,83</a>]. SNF472 is an inhibitor of vascular calcification that directly targets the deposition of solid calcium (hydroxyapatite) in the cardiovascular system. SNF472 has received orphan drug status and was previously shown to attenuate progression of coronary artery calcium and aortic valve calcification in patients with end-stage kidney disease receiving hemodialysis [<a href="#rid84">84</a>]. SNF472 is being investigated for the treatment of calciphylaxis in patients with end-stage kidney disease in an ongoing phase 3 study (NCT04195906).</p><p class="headingAnchor" id="H3008775586"><span class="h2">Factor Xa inhibition</span><span class="headingEndMark"> — </span>The combination of low-dose anticoagulation and antiplatelet therapy, so-called dual pathway inhibition, has been shown to be beneficial in preventing ischemic events in patients with PAD. The COMPASS trial demonstrated significant reductions in MACE and major adverse limb events with <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg twice daily plus <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> versus aspirin alone in 27,395 patients with stable atherosclerotic cardiovascular disease, including chronic PAD [<a href="#rid85">85</a>]. VOYAGER PAD also showed significant reduction in severe cardiovascular and limb events with this same regimen among 6564 patients undergoing endovascular or surgical lower extremity revascularization for symptomatic PAD [<a href="#rid86">86</a>]. Another trial of dual pathway inhibition studying <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> 2.5 mg twice daily plus aspirin versus <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> plus aspirin among 200 patients with PAD and critical limb ischemia undergoing infrapopliteal endovascular revascularization is planned [<a href="#rid87">87</a>]. However, this study is unlikely to provide robust data on efficacy and safety to support use of this combination in this clinical setting.</p><p class="headingAnchor" id="H2561511376"><span class="h2">Lipoprotein(a) reduction</span><span class="headingEndMark"> — </span>Lipoprotein(a) is a low-density lipoprotein particle with proatherogenic, proinflammatory, and prothrombotic effects that has been associated with development of atherosclerotic cardiovascular disease, including PAD, and poor cardiovascular prognosis [<a href="#rid88">88,89</a>]. Lipoprotein(a) apheresis reduces levels of lipoprotein(a) and has been shown to reduce risk of cardiovascular events among patients with coronary artery disease [<a href="#rid90">90-93</a>]. Among patients with PAD, small observational studies have demonstrated apheresis is associated with reductions in MACE, coronary and noncoronary artery revascularization procedures, and leg pain, and increases in mean walking distance and resting ABI [<a href="#rid91">91,94,95</a>]. The efficacy of apheresis in PAD has not yet been proven with randomized trials, however.</p><p>No approved pharmacologic therapies that specifically target lipoprotein(a) are available. However, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and <a class="drug drug_general" data-topicid="134700" href="/d/drug information/134700.html" rel="external">inclisiran</a>, a small interfering RNA that inhibits hepatic synthesis of PCSK9, have been shown to reduce lipoprotein(a) levels by approximately 25 percent [<a href="#rid96">96</a>]. Treatment with PSCK9i was demonstrated to reduce risk of PAD events among patients with atherosclerotic cardiovascular disease, with the reduction in risk associated with both baseline lipoprotein(a) and LDL-C levels [<a href="#rid97">97</a>]. A hepatocyte-directed antisense oligonucleotide, AKCEA-APO(a)-L<sub>Rx</sub>, was shown to significantly reduce lipoprotein(a) levels among patients with established cardiovascular disease [<a href="#rid98">98</a>]. Two studies examining small interfering RNAs directed against Apo(a) in patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a) levels are planned or have begun enrollment (NCT04270760, NCT04606602).</p><p class="headingAnchor" id="H3421961605"><span class="h2">Icosapent ethyl</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86044" href="/d/drug information/86044.html" rel="external">Icosapent ethyl</a> (IPE) is a purified and stable eicosapentaenoic acid ethyl ester that lowers triglyceride levels [<a href="#rid99">99</a>]. It may also have anti-inflammatory and antioxidative properties [<a href="#rid100">100</a>]. REDUCE-IT showed benefit of IPE versus placebo in patients with established cardiovascular disease or diabetes and other risk factors in reducing cardiovascular death, nonfatal myocardial infarction, coronary revascularization, or unstable angina [<a href="#rid101">101</a>]. In a subgroup analysis of REDUCE-IT, patients with PAD were at higher risk for first and total events, and IPE versus placebo provided consistent cardiovascular benefit in patients with or without PAD for first (p interaction = 0.58) and total (p interaction = 0.78) events [<a href="#rid102">102</a>].</p><p class="headingAnchor" id="H2513254798"><span class="h2">Fenofibrates</span><span class="headingEndMark"> — </span>Diabetes mellitus (DM) is a frequent comorbid condition in patients with PAD and is one of the most common causes of nontraumatic lower-extremity amputation. In the <a class="drug drug_general" data-topicid="91482" href="/d/drug information/91482.html" rel="external">fenofibrate</a> intervention and event lowering in diabetes (FIELD) study, treatment of 9.795 patients with type 2 DM with fenofibrate versus placebo was associated with a lower risk of any amputation (HR 0.64, 95% CI 0.44-0.94). Use of fibrates to improve limb outcomes in patients with PAD has not been reported.</p><p class="headingAnchor" id="H135434320"><span class="h1">STEM CELL THERAPY</span><span class="headingEndMark"> — </span>Stem cell therapy involves the transplantation of hematopoietic or bone marrow stem cells to stimulate blood vessel growth and new blood vessel formation [<a href="#rid103">103-105</a>]. Adult stem cells are thought to be present in most, but not all, tissues and to persist throughout life. (See  <a class="medical medical_review" href="/d/html/14598.html" rel="external">"Overview of stem cells"</a> and  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a> and  <a class="medical medical_review" href="/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p>Bone marrow-derived, adipose-derived stem cell therapy [<a href="#rid106">106-110</a>] and placenta-derived [<a href="#rid111">111</a>] stem cells have been studied for the treatment of PAD [<a href="#rid112">112-115</a>]. Bone marrow can be obtained by direct aspiration. Subcutaneous injection of granulocyte-macrophage colony stimulating factor (GM-CSF) can be used to mobilize mononuclear cells from the bone marrow, which can then be collected in the peripheral blood [<a href="#rid116">116-118</a>]. Flow cytometry has also been used to detect cells that express high levels of the aldehyde dehydrogenase activity, and such aldehyde dehydrogenase bright cell populations have been sorted from bone marrow and peripheral blood and used to treat patients with claudication and chronic limb-threatening ischemia [<a href="#rid119">119-121</a>]. </p><p>A trial using aldehyde dehydrogenase bright cells for the treatment of claudication has been completed [<a href="#rid121">121</a>]. Although intramuscular injection of these cells was safe and feasible, there was no improvement in peak walking time or difference in physiologic magnetic resonance imaging-derived end points. Another approach was to give patients GM-CSF alone or in combination with supervised exercise training [<a href="#rid122">122</a>]. While exercise training worked as expected, GM-CSF did not improve exercise performance. </p><p>A 2011 Cochrane review that limited analysis to intramuscular transplantation of mononuclear cells (excluding intraarterial injection) identified two small trials (n = 57) [<a href="#rid112">112</a>]. An updated 2014 review found no additional studies deemed of sufficient quality to merit inclusion [<a href="#rid123">123</a>]. Each of the included studies found a significantly smaller proportion of participants in the stem cell therapy group requiring amputation. One trial compared stem cell therapy to standard therapy, while the other compared mobilized peripheral mononuclear cells with daily intravenous prostaglandin E1 injections (control group) [<a href="#rid124">124</a>]. Pain, ankle-brachial index (mean increase 0.13 versus 0.02), and pain-free walking distance (mean increase 306 versus 79 meters) were significantly improved compared with the PGE1 group. The rate of healing of ischemic ulcers was increased in the stem cell therapy group (14 of 18 versus 7 of 18).</p><p>A systematic review and meta-analysis [<a href="#rid125">125</a>] evaluated outcomes of randomized and observational studies of autologous cell therapy in patients with limb-threatening ischemia or PAD without revascularization options [<a href="#rid124">124,126-136</a>]. Although cell therapy appeared to decrease rest pain and amputation risk and increase ankle-brachial index, the efficacy was not significant after limiting the analysis to randomized placebo-controlled studies, and efficacy was not present after excluding randomized controlled studies with high risk of bias. The results of several subsequent small studies have been reported [<a href="#rid116">116-118,137-145</a>]. A later meta-analysis reported significant improvement in ulcer healing and reductions in any amputation and pain with stem cell therapy but no difference in major limb salvage [<a href="#rid146">146</a>]. The use of stem cells primarily for the treatment of chronic limb-threatening ischemia and "no option" patients remains an active area of interest with several study protocols in progress or completed but not published (NCT03304821, NCT01745744, NCT03968198).</p><p class="headingAnchor" id="H135435079"><span class="h1">THERAPEUTIC ANGIOGENESIS</span><span class="headingEndMark"> — </span>The term "angiogenesis" broadly refers to formation of new vessels. The goal of therapeutic angiogenesis is to induce development of new arterial vessels to improve perfusion of ischemic tissue. The main processes leading to new vessel formation are described elsewhere. (See  <a class="medical medical_review" href="/d/html/1537.html" rel="external">"Therapeutic angiogenesis for management of refractory angina"</a>.)</p><p>A number of angiogenic growth factors stimulate blood vessel growth and can be administered as recombinant protein or naked DNA via intra-arterial or intramuscular injection [<a href="#rid147">147</a>]. Preclinical studies suggested that angiogenic growth factors can stimulate the development of collateral arteries [<a href="#rid148">148,149</a>]. Early studies evaluating the safety and efficacy in patients with PAD had variable results [<a href="#rid150">150-153</a>]. </p><p>A later systematic review [<a href="#rid154">154</a>] identified 12 trials performed between 2003 and 2011, 3 in patients with claudication [<a href="#rid155">155-157</a>], 9 in patients with chronic limb-threatening ischemia [<a href="#rid158">158-165</a>], and 1 with both [<a href="#rid166">166</a>]. Various angiogenic factors were used, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), developmental endothelial locus-1 (Del-1), and hypoxia-inducible factor-1 alpha (HIF-1alpha). A meta-analysis did not find any significant treatment effect overall, or for claudication or for chronic limb-threatening ischemia, with respect to the rate of amputation, ulcer healing, or all-cause mortality. </p><p class="headingAnchor" id="H135432872"><span class="h1">OTHER THERAPIES</span><span class="headingEndMark"> — </span>A variety of factors can limit the successful performance of recommended exercise therapy regimens in patients with PAD. Other therapies aimed at overcoming some of the limitations have been investigated and include spinal cord stimulation, transcutaneous nerve stimulation, heat therapy, pneumatic compression therapy, and extracorporeal shockwave therapy. The quality of evidence for these therapies is overall low and as such, these therapies cannot be recommended. The available studies are reviewed briefly below. </p><p class="headingAnchor" id="H135432878"><span class="h2">Spinal cord stimulation</span><span class="headingEndMark"> — </span>Initial uncontrolled studies suggested that spinal cord stimulation (SCS) was effective for pain relief and might prevent or delay amputation and improve limb survival [<a href="#rid167">167,168</a>]. A systematic review identified six studies involving 450 patients [<a href="#rid169">169</a>]. The risk of limb loss after 12 months was significantly lower in the spinal cord stimulation group (risk ratio [RR] 0.71, 95% CI 0.56-0.90). Overall, there were no significant differences in ulcer healing. Complications of spinal cord stimulation consisted of implantation problems, changes in stimulation requiring reintervention, and, less frequently, infections of the lead or pulse generator pocket. The benefits of SCS must be considered against the possibility of harm due to mostly mild complications and the additional cost of the device and implantation. </p><p class="headingAnchor" id="H508800181"><span class="h2">Nerve stimulation</span><span class="headingEndMark"> — </span>Neuromuscular electrical stimulation (NMES) has been explored as an adjunct to reduce PAD symptoms as well as for improving exercise therapy [<a href="#rid170">170</a>]. NMES causes muscle contraction as well as sensory stimulation [<a href="#rid171">171-174</a>], and in patients with PAD, NMES to the lower legs has also been reported to cause vasodilatation [<a href="#rid175">175</a>]. In a pilot trial that randomly assigned 42 patients to footplate NMES and supervised exercise (ie, combined therapy) or supervised exercise therapy alone for six weeks, initial claudication distance was 46 percent greater in the combined therapy group, but maximum claudication distance was similar between the groups, indicating no benefit on peak exercise performance [<a href="#rid174">174</a>]. Intermittent claudication questionnaire scores were also improved for the combined therapy group. Other clinically important outcomes (eg, PAD progression) were not evaluated. Another study evaluating NMES in the management of patients with claudication has competed but has not yet published results (NCT03446027). </p><p>In addition to NMES, the effects of transcutaneous electrical nerve stimulation (TENS), which only induces sensory stimulation and mainly provides analgesia, is also under investigation in PAD patients. The TENS-PAD study is an ongoing placebo-controlled, double-blind, multicenter randomized trial that will assess the effect of TENS on the primary outcome of pain-free walking distance in 100 patients with PAD and claudication [<a href="#rid176">176</a>]. Other studies of TENS in PAD patients with claudication are also ongoing or have not yet published results (NCT03462472, NCT03204825, NCT03512912).</p><p class="headingAnchor" id="H977115034"><span class="h2">Pneumatic compression</span><span class="headingEndMark"> — </span>Intermittent pneumatic compression (IPC) appears to improve walking ability and ankle-brachial indices in PAD patients with claudication, with effects maintained 12 months after cessation of therapy [<a href="#rid177">177-179</a>]. Mechanisms for this benefit include drainage of veins of the foot and calf, depending on the level of compression, with an increase in the arteriovenous pressure gradient and enhanced arterial inflow [<a href="#rid178">178</a>], as well as the potential promotion of arterial collateralization [<a href="#rid177">177</a>].</p><p class="headingAnchor" id="H3758916725"><span class="h2">Intermittent negative pressure therapy</span><span class="headingEndMark"> — </span>Intermittent vacuum therapy alternately applies negative pressure and atmospheric pressure to the lower extremities. Outcomes of studies evaluating intermittent negative pressure therapy are conflicting. A randomized comparison of intermittent vacuum therapy plus lifestyle changes versus lifestyle changes alone in 48 patients with PAD showed no difference in toe pressures, walking capacity, claudication symptoms, physical activity, or self-rated health between treatment groups [<a href="#rid180">180</a>]. In a Dutch study, walking distance was similar between those randomly assigned to intermittent vacuum therapy (-50 mBar [-37.5 mmHg]) or control (-5 mBar [-4 mmHg]), and both groups had a similar improvement in quality of life at 6- and 12-week follow-up [<a href="#rid181">181</a>]. Thus, intermittent vacuum therapy did not confer any additional beneficial effects in patients with intermittent claudication undergoing a standardized supervised exercise therapy program. In another trial in which intermittent vacuum therapy (-40 mmHg) was applied for one hour twice daily for two weeks, mean walking distance was modestly increased for intermittent vacuum therapy compared with controls, although not significant [<a href="#rid182">182</a>]. </p><p class="headingAnchor" id="H1393617097"><span class="h2">Heat therapy</span><span class="headingEndMark"> — </span>Passive heat therapy has also been reported to improve lower limb perfusion, enhance vascular function, and reduce blood pressure in PAD patients, potentially via alterations in arterial shear stress [<a href="#rid183">183-185</a>]. In a small sham-controlled randomized study, leg heat therapy reduced systolic blood pressure and plasma levels of endothelin-1, and there was a trend for increased peak walking time (911±69 sec vs 954±77 sec, p = 0.059). Heat therapy is currently under investigation among PAD patients with claudication in other ongoing studies (NCT03435835, NCT02770547, NCT03763331). </p><p class="headingAnchor" id="H3569277219"><span class="h2">Extracorporeal shockwave therapy</span><span class="headingEndMark"> — </span>Extracorporeal shockwave therapy (ESWT) is a relatively novel therapy for treating patients with PAD. Historically, ESWT has been used in orthopedics for delayed bone healing and in wound care [<a href="#rid186">186,187</a>]. In ischemic heart disease, ESWT has shown promise for reducing angina [<a href="#rid188">188</a>], improving left ventricular ejection fraction in ischemic cardiomyopathy [<a href="#rid189">189</a>], and improving myocardial perfusion on thallium scintography [<a href="#rid190">190</a>]. </p><p>For patients with PAD, several studies have shown improvements in lower limb blood flow and walking ability with ESWT [<a href="#rid191">191-194</a>]. Although the studies were small, a systematic review of five studies of ESWT in symptomatic PAD found significant improvements in pain-free walking distance and maximum walking distance [<a href="#rid195">195</a>]. The exact mechanisms by which ESWT achieves these results is unclear but is thought to be related to mechanotransduction, whereby mechanical stimuli are transformed into chemical signals and angiogenesis [<a href="#rid196">196</a>]. A trial examining the effect of ESWT on the primary outcome of maximum walking distance in claudication has been completed, but results are not yet available (NCT02652078).</p><p class="headingAnchor" id="H2469311887"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117201.html" rel="external">"Society guideline links: Occlusive carotid, aortic, renal, mesenteric, and peripheral atherosclerotic disease"</a>.)</p><p class="headingAnchor" id="H4814783"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Claudication</strong> – Therapies under investigation for claudication are aimed at improving ambulation to avoid the need for revascularization (see <a class="local">'Pharmacologic agents'</a> above). Among the many pharmacologic agents studied for the treatment of patients with claudication, convincing evidence of benefit is available only for <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> and naftidrofuryl. These and other potentially beneficial pharmacologic agents are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Pharmacologic therapy to improve walking'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic limb-threatening ischemia</strong> – The best therapeutic option for patients with severe peripheral artery disease (PAD; ie, chronic limb-threatening ischemia manifesting as rest pain, ischemic ulceration, or gangrene) is revascularization (percutaneous or surgical). Therapies under investigation for treating chronic limb-threatening ischemia, primarily for patients who are poor candidates for revascularization due to severe medical comorbidities, are aimed at promoting healing of ischemic ulcers or altering the perception of ischemic pain. The clinical use of these agents is not yet recommended. (See <a class="local">'Pharmacologic agents'</a> above and <a class="local">'Stem cell therapy'</a> above and <a class="local">'Therapeutic angiogenesis'</a> above and <a class="local">'Other therapies'</a> above.)</p><p></p><p class="headingAnchor" id="H3082170609"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William R Hiatt, MD, now deceased, who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Emile R Mohler, III, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.</a></li><li><a class="nounderline abstract_t">Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:815S.</a></li><li><a class="nounderline abstract_t">Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135:e686.</a></li><li><a class="nounderline abstract_t">Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rev Esp Cardiol (Engl Ed) 2018; 71:111.</a></li><li><a class="nounderline abstract_t">Gardner AW, Parker DE, Montgomery PS, Blevins SM. Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral artery disease: a randomized controlled trial. J Am Heart Assoc 2014; 3:e001107.</a></li><li><a class="nounderline abstract_t">Golledge J, Singh TP, Alahakoon C, et al. Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease. Br J Surg 2019; 106:319.</a></li><li><a class="nounderline abstract_t">McDermott MM, Spring B, Berger JS, et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA 2018; 319:1665.</a></li><li><a class="nounderline abstract_t">McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 2013; 310:57.</a></li><li><a class="nounderline abstract_t">Collins TC, Lunos S, Carlson T, et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial. Diabetes Care 2011; 34:2174.</a></li><li><a class="nounderline abstract_t">Brass EP. Intermittent claudication: new targets for drug development. Drugs 2013; 73:999.</a></li><li><a class="nounderline abstract_t">Shalhoub J, Davies AH. Adjunctive pharmacotherapies for intermittent claudication--NICE guidance. Heart 2012; 98:244.</a></li><li><a class="nounderline abstract_t">Qamar A, Rader DJ. Effect of interleukin 1β inhibition in cardiovascular disease. Curr Opin Lipidol 2012; 23:548.</a></li><li><a class="nounderline abstract_t">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119.</a></li><li><a class="nounderline abstract_t">Liberale L, Montecucco F, Schwarz L, et al. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res 2021; 117:411.</a></li><li><a class="nounderline abstract_t">Russell KS, Yates DP, Kramer CM, et al. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease. Vasc Med 2019; 24:414.</a></li><li><a class="nounderline abstract_t">Jarr KU, Kojima Y, Weissman IL, Leeper NJ. 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis. Arterioscler Thromb Vasc Biol 2022; 42:e145.</a></li><li><a class="nounderline abstract_t">Kojima Y, Volkmer JP, McKenna K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 2016; 536:86.</a></li><li><a class="nounderline abstract_t">Jarr KU, Nakamoto R, Doan BH, et al. Effect of CD47 Blockade on Vascular Inflammation. N Engl J Med 2021; 384:382.</a></li><li><a class="nounderline abstract_t">Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000; :CD000987.</a></li><li><a class="nounderline abstract_t">Carrero JJ, López-Huertas E, Salmerón LM, et al. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005; 135:1393.</a></li><li><a class="nounderline abstract_t">Violi F, Loffredo L, Mancini A, Marcoccia A. Antioxidants in peripheral arterial disease. Curr Drug Targets 2003; 4:651.</a></li><li><a class="nounderline abstract_t">Arosio E, De Marchi S, Zannoni M, et al. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2002; 77:754.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Gainer JL, Whitten K, et al. Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication. Vasc Med 2011; 16:346.</a></li><li><a class="nounderline abstract_t">Kaperonis EA, Liapis CD, Kakisis JD, et al. Inflammation and Chlamydia pneumoniae infection correlate with the severity of peripheral arterial disease. Eur J Vasc Endovasc Surg 2006; 31:509.</a></li><li><a class="nounderline abstract_t">Lippi G, Franchini M, Montagnana M, et al. Dark chocolate: consumption for pleasure or therapy? J Thromb Thrombolysis 2009; 28:482.</a></li><li><a class="nounderline abstract_t">Hammer A, Koppensteiner R, Steiner S, et al. Dark chocolate and vascular function in patients with peripheral artery disease: a randomized, controlled cross-over trial. Clin Hemorheol Microcirc 2015; 59:145.</a></li><li><a class="nounderline abstract_t">Loffredo L, Perri L, Catasca E, et al. Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease. J Am Heart Assoc 2014; 3.</a></li><li><a class="nounderline abstract_t">McDermott MM, Criqui MH, Domanchuk K, et al. Cocoa to Improve Walking Performance in Older People With Peripheral Artery Disease: The COCOA-PAD Pilot Randomized Clinical Trial. Circ Res 2020; 126:589.</a></li><li><a class="nounderline abstract_t">Tenore GC, D'Avino M, Caruso D, et al. Effect of Annurca Apple Polyphenols on Intermittent Claudication in Patients With Peripheral Artery Disease. Am J Cardiol 2019; 123:847.</a></li><li><a class="nounderline abstract_t">Sandoo A, van Zanten JJ, Metsios GS, et al. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J 2010; 4:302.</a></li><li><a class="nounderline abstract_t">Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci 2013; 9:1057.</a></li><li><a class="nounderline abstract_t">de Haro Miralles J, Martínez-Aguilar E, Florez A, et al. Nitric oxide: link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs. Interact Cardiovasc Thorac Surg 2009; 9:107.</a></li><li><a class="nounderline abstract_t">Kapil V, Milsom AB, Okorie M, et al. Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension 2010; 56:274.</a></li><li><a class="nounderline abstract_t">Kenjale AA, Ham KL, Stabler T, et al. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. J Appl Physiol (1985) 2011; 110:1582.</a></li><li><a class="nounderline abstract_t">Shiva S. Nitrite: A Physiological Store of Nitric Oxide and Modulator of Mitochondrial Function. Redox Biol 2013; 1:40.</a></li><li><a class="nounderline abstract_t">Cermak NM, Gibala MJ, van Loon LJ. Nitrate supplementation's improvement of 10-km time-trial performance in trained cyclists. Int J Sport Nutr Exerc Metab 2012; 22:64.</a></li><li><a class="nounderline abstract_t">Lansley KE, Winyard PG, Fulford J, et al. Dietary nitrate supplementation reduces the O2 cost of walking and running: a placebo-controlled study. J Appl Physiol (1985) 2011; 110:591.</a></li><li><a class="nounderline abstract_t">Bailey SJ, Winyard P, Vanhatalo A, et al. Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. J Appl Physiol (1985) 2009; 107:1144.</a></li><li><a class="nounderline abstract_t">Martin K, Smee D, Thompson KG, Rattray B. No improvement of repeated-sprint performance with dietary nitrate. Int J Sports Physiol Perform 2014; 9:845.</a></li><li><a class="nounderline abstract_t">Wilkerson DP, Hayward GM, Bailey SJ, et al. Influence of acute dietary nitrate supplementation on 50 mile time trial performance in well-trained cyclists. Eur J Appl Physiol 2012; 112:4127.</a></li><li><a class="nounderline abstract_t">Peacock O, Tjønna AE, James P, et al. Dietary nitrate does not enhance running performance in elite cross-country skiers. Med Sci Sports Exerc 2012; 44:2213.</a></li><li><a class="nounderline abstract_t">Boorsma RK, Whitfield J, Spriet LL. Beetroot juice supplementation does not improve performance of elite 1500-m runners. Med Sci Sports Exerc 2014; 46:2326.</a></li><li><a class="nounderline abstract_t">Wood DL, Sheps SG, Elveback LR, Schirger A. Cold pressor test as a predictor of hypertension. Hypertension 1984; 6:301.</a></li><li><a class="nounderline abstract_t">Schindler TH, Hornig B, Buser PT, et al. Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol 2003; 23:495.</a></li><li><a class="nounderline abstract_t">Hughes WE, Treichler DP, Ueda K, et al. Sodium nitrate supplementation improves blood pressure reactivity in patients with peripheral artery disease. Nutr Metab Cardiovasc Dis 2022; 32:710.</a></li><li><a class="nounderline abstract_t">Woessner MN, VanBruggen MD, Pieper CF, et al. Combined Dietary Nitrate and Exercise Intervention in Peripheral Artery Disease: Protocol Rationale and Design. JMIR Res Protoc 2017; 6:e139.</a></li><li><a class="nounderline abstract_t">Woessner M, VanBruggen MD, Pieper CF, et al. Beet the Best? Circ Res 2018; 123:654.</a></li><li><a class="nounderline abstract_t">Kumar D, Branch BG, Pattillo CB, et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci U S A 2008; 105:7540.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Hiatt WR, Gornik HL, et al. Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function. Vasc Med 2014; 19:9.</a></li><li><a class="nounderline abstract_t">Dezfulian C, Alekseyenko A, Dave KR, et al. Nitrite therapy is neuroprotective and safe in cardiac arrest survivors. Nitric Oxide 2012; 26:241.</a></li><li><a class="nounderline abstract_t">Dezfulian C, Shiva S, Alekseyenko A, et al. Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. Circulation 2009; 120:897.</a></li><li><a class="nounderline abstract_t">Chiodi H, Mohler JG. Nonautocatalytic methemoglobin formation by sodium nitrite under aerobic and anaerobic conditions. Environ Res 1987; 44:45.</a></li><li><a class="nounderline abstract_t">Chin-Dusting JP, Willems L, Kaye DM. L-arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 2007; 116:428.</a></li><li><a class="nounderline abstract_t">Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295:58.</a></li><li><a class="nounderline abstract_t">Rochette L, Lorin J, Zeller M, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther 2013; 140:239.</a></li><li><a class="nounderline abstract_t">Kashyap VS, Lakin RO, Campos P, et al. The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease. J Vasc Surg 2017; 66:187.</a></li><li><a class="nounderline abstract_t">Wilson AM, Harada R, Nair N, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007; 116:188.</a></li><li><a class="nounderline abstract_t">Gonzales JU, Raymond A, Ashley J, Kim Y. Does l-citrulline supplementation improve exercise blood flow in older adults? Exp Physiol 2017; 102:1661.</a></li><li><a class="nounderline abstract_t">Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 48:2539.</a></li><li><a class="nounderline abstract_t">Brass EP, Cooper LT, Morgan RE, Hiatt WR. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg 2012; 55:381.</a></li><li><a class="nounderline abstract_t">Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2013; :CD000986.</a></li><li><a class="nounderline abstract_t">Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010; :CD006544.</a></li><li><a class="nounderline abstract_t">Lawall H, Pokrovsky A, Checinski P, et al. Efficacy and Safety of Alprostadil in Patients with Peripheral Arterial Occlusive Disease Fontaine Stage IV: Results of a Placebo Controlled Randomised Multicentre Trial (ESPECIAL). Eur J Vasc Endovasc Surg 2017; 53:559.</a></li><li><a class="nounderline abstract_t">Belch JJ, Bell PR, Creissen D, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95:2298.</a></li><li><a class="nounderline abstract_t">Luzzi R, Belcaro G, Ippolito E, et al. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs]. Minerva Cardioangiol 2012; 60:405.</a></li><li><a class="nounderline abstract_t">Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med 1999; 130:412.</a></li><li><a class="nounderline abstract_t">Nehler MR, Brass EP, Anthony R, et al. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg 2007; 45:953.</a></li><li><a class="nounderline abstract_t">Brass EP, Anthony R, Dormandy J, et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006; 43:752.</a></li><li><a class="nounderline abstract_t">Creager MA, Pande RL, Hiatt WR. A randomized trial of iloprost in patients with intermittent claudication. Vasc Med 2008; 13:5.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Klugherz B, Goldman R, et al. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc Med 2000; 5:231.</a></li><li><a class="nounderline abstract_t">Berman S, Quick R, Yoder P, et al. Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study. Vascular 2006; 14:142.</a></li><li><a class="nounderline abstract_t">Fernandez B, Strootman D. The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature. Angiology 2006; 57:99.</a></li><li><a class="nounderline abstract_t">Vietto V, Franco JV, Saenz V, et al. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2018; 1:CD006544.</a></li><li><a class="nounderline abstract_t">Shahin Y, Cockcroft JR, Chetter IC. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br J Surg 2013; 100:1154.</a></li><li><a class="nounderline abstract_t">Ahimastos AA, Walker PJ, Askew C, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013; 309:453.</a></li><li><a class="nounderline abstract_t">Shahin Y, Mazari F, Chetter I. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg 2011; 9:209.</a></li><li class="breakAll">Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities (STERILE, NCT00914316). Available from: https://www.clinicaltrials.gov/ct2/show/NCT00914316. (Accessed on August 24, 2020).</li><li><a class="nounderline abstract_t">Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834.</a></li><li><a class="nounderline abstract_t">Verma S, Rasmussen S, Saevereid HA, Ripa MS. Liraglutide and semaglutide reduce cardiovascular events in patients with type 2 diabetes and peripheral arterial disease. Circulation 2019; 140:A11456.</a></li><li><a class="nounderline abstract_t">Dhatariya K, Bain SC, Buse JB, et al. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care 2018; 41:2229.</a></li><li><a class="nounderline abstract_t">Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112.</a></li><li><a class="nounderline abstract_t">Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938.</a></li><li><a class="nounderline abstract_t">Palit S, Kendrick J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des 2014; 20:5829.</a></li><li><a class="nounderline abstract_t">Raggi P, Bellasi A, Bushinsky D, et al. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study. Circulation 2020; 141:728.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377:1319.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 2020; 382:1994.</a></li><li><a class="nounderline abstract_t">Biagioni RB, Lopes RD, Agati LB, et al. Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. Am Heart J 2020; 227:100.</a></li><li><a class="nounderline abstract_t">Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41:2313.</a></li><li><a class="nounderline abstract_t">Kosmas CE, Silverio D, Sourlas A, et al. Role of lipoprotein (a) in peripheral arterial disease. Ann Transl Med 2019; 7:S242.</a></li><li><a class="nounderline abstract_t">Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6:229.</a></li><li><a class="nounderline abstract_t">Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128:2567.</a></li><li><a class="nounderline abstract_t">Roeseler E, Julius U, Heigl F, et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol 2016; 36:2019.</a></li><li><a class="nounderline abstract_t">Schatz U, Tselmin S, Müller G, et al. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study. Atheroscler Suppl 2017; 30:246.</a></li><li><a class="nounderline abstract_t">Poller WC, Dreger H, Morgera S, et al. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a). Atheroscler Suppl 2015; 18:187.</a></li><li><a class="nounderline abstract_t">Poller WC, Berger A, Dreger H, et al. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. Atheroscler Suppl 2017; 30:174.</a></li><li><a class="nounderline abstract_t">O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 2019; 139:1483.</a></li><li><a class="nounderline abstract_t">Schwartz GG, Steg PG, Szarek M, et al. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 2020; 141:1608.</a></li><li><a class="nounderline abstract_t">Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med 2020; 382:244.</a></li><li><a class="nounderline abstract_t">Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984.</a></li><li><a class="nounderline abstract_t">Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013; 13:37.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019; 380:11.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Steg PG, Miller M, et al. Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD. Circulation 2021; 144:A10627.</a></li><li><a class="nounderline abstract_t">Ruiz-Salmeron R, de la Cuesta-Diaz A, Constantino-Bermejo M, et al. Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. Cell Transplant 2011; 20:1629.</a></li><li><a class="nounderline abstract_t">Lasala GP, Minguell JJ. Vascular disease and stem cell therapies. Br Med Bull 2011; 98:187.</a></li><li><a class="nounderline abstract_t">Idei N, Soga J, Hata T, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv 2011; 4:15.</a></li><li><a class="nounderline abstract_t">Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J 2012; 76:1750.</a></li><li><a class="nounderline abstract_t">Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 2014; 16:245.</a></li><li><a class="nounderline abstract_t">Zhi K, Gao Z, Bai J, et al. Application of adipose-derived stem cells in critical limb ischemia. Front Biosci (Landmark Ed) 2014; 19:768.</a></li><li><a class="nounderline abstract_t">Cai A, Qiu R, Li L, et al. Atorvastatin treatment of rats with ischemia-reperfusion injury improves adipose-derived mesenchymal stem cell migration and survival via the SDF-1α/CXCR-4 axis. PLoS One 2013; 8:e79100.</a></li><li><a class="nounderline abstract_t">Acosta L, Hmadcha A, Escacena N, et al. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes 2013; 62:4266.</a></li><li><a class="nounderline abstract_t">Prather WR, Toren A, Meiron M, et al. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy 2009; 11:427.</a></li><li><a class="nounderline abstract_t">Moazzami K, Majdzadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev 2011; :CD008347.</a></li><li><a class="nounderline abstract_t">Benoit E, O'Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplant 2013; 22:545.</a></li><li><a class="nounderline abstract_t">Teraa M, Sprengers RW, van der Graaf Y, et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013; 258:922.</a></li><li><a class="nounderline abstract_t">Frangogiannis NG. Cell therapy for peripheral artery disease. Curr Opin Pharmacol 2018; 39:27.</a></li><li><a class="nounderline abstract_t">Poole J, Mavromatis K, Binongo JN, et al. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial. JAMA 2013; 310:2631.</a></li><li><a class="nounderline abstract_t">Domanchuk K, Ferrucci L, Guralnik JM, et al. Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: the PROPEL Study. Contemp Clin Trials 2013; 36:502.</a></li><li><a class="nounderline abstract_t">van Royen N, Schirmer SH, Atasever B, et al. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005; 112:1040.</a></li><li><a class="nounderline abstract_t">Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells 2011; 29:570.</a></li><li><a class="nounderline abstract_t">Keller LH. Bone marrow-derived aldehyde dehydrogenase-bright stem and progenitor cells for ischemic repair. Congest Heart Fail 2009; 15:202.</a></li><li><a class="nounderline abstract_t">Perin EC, Murphy MP, March KL, et al. Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). Circulation 2017; 135:1417.</a></li><li><a class="nounderline abstract_t">McDermott MM, Ferrucci L, Tian L, et al. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. JAMA 2017; 318:2089.</a></li><li><a class="nounderline abstract_t">Moazzami K, Moazzami B, Roohi A, et al. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev 2014; :CD008347.</a></li><li><a class="nounderline abstract_t">Huang P, Li S, Han M, et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28:2155.</a></li><li><a class="nounderline abstract_t">Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. Circ Res 2017; 120:1326.</a></li><li><a class="nounderline abstract_t">Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360:427.</a></li><li><a class="nounderline abstract_t">Dash NR, Dash SN, Routray P, et al. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res 2009; 12:359.</a></li><li><a class="nounderline abstract_t">Ozturk A, Kucukardali Y, Tangi F, et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J Diabetes Complications 2012; 26:29.</a></li><li class="breakAll">Debin L,Youzhao J, Ziwen L, et al. Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. J Med Coll PLA 2008;23:106.</li><li class="breakAll">Barc P, Skora J, Pupka A, et al. Bone-marrow cells in therapy of critical limb ischaemia of lower extremities-Own experience. Acta Angiolog 2006;12:155.</li><li><a class="nounderline abstract_t">Arai M, Misao Y, Nagai H, et al. Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006; 70:1093.</a></li><li><a class="nounderline abstract_t">Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4:26.</a></li><li><a class="nounderline abstract_t">Benoit E, O'Donnell TF Jr, Iafrati MD, et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011; 9:165.</a></li><li><a class="nounderline abstract_t">Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92:26.</a></li><li><a class="nounderline abstract_t">Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther 2012; 20:1280.</a></li><li><a class="nounderline abstract_t">Procházka V, Gumulec J, Jalůvka F, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010; 19:1413.</a></li><li><a class="nounderline abstract_t">Teraa M, Sprengers RW, Schutgens RE, et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation 2015; 131:851.</a></li><li><a class="nounderline abstract_t">Mohammadzadeh L, Samedanifard SH, Keshavarzi A, et al. Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Exp Clin Endocrinol Diabetes 2013; 121:48.</a></li><li><a class="nounderline abstract_t">Perin EC, Silva GV, Zheng Y, et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012; 163:415.</a></li><li><a class="nounderline abstract_t">Perin EC, Silva G, Gahremanpour A, et al. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011; 78:1060.</a></li><li><a class="nounderline abstract_t">Franz RW, Shah KJ, Johnson JD, et al. Short- to mid-term results using autologous bone-marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease. Vasc Endovascular Surg 2011; 45:398.</a></li><li><a class="nounderline abstract_t">Lasala GP, Silva JA, Minguell JJ. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. J Thorac Cardiovasc Surg 2012; 144:377.</a></li><li><a class="nounderline abstract_t">Gupta PK, Chullikana A, Parakh R, et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med 2013; 11:143.</a></li><li><a class="nounderline abstract_t">Arici V, Perotti C, Fabrizio C, et al. Autologous immuno magnetically selected CD133+ stem cells in the treatment of no-option critical limb ischemia: clinical and contrast enhanced ultrasound assessed results in eight patients. J Transl Med 2015; 13:342.</a></li><li><a class="nounderline abstract_t">Franz RW, Shah KJ, Pin RH, et al. Autologous bone marrow mononuclear cell implantation therapy is an effective limb salvage strategy for patients with severe peripheral arterial disease. J Vasc Surg 2015; 62:673.</a></li><li><a class="nounderline abstract_t">Gao W, Chen D, Liu G, Ran X. Autologous stem cell therapy for peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther 2019; 10:140.</a></li><li><a class="nounderline abstract_t">Shimamura M, Nakagami H, Taniyama Y, Morishita R. Gene therapy for peripheral arterial disease. Expert Opin Biol Ther 2014; 14:1175.</a></li><li><a class="nounderline abstract_t">Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86:1198.</a></li><li><a class="nounderline abstract_t">Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93:662.</a></li><li><a class="nounderline abstract_t">Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359:2053.</a></li><li><a class="nounderline abstract_t">Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114.</a></li><li><a class="nounderline abstract_t">Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108:1933.</a></li><li><a class="nounderline abstract_t">De Haro J, Acin F, Lopez-Quintana A, et al. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 2009; 24:321.</a></li><li><a class="nounderline abstract_t">Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials. Vasa 2013; 42:331.</a></li><li><a class="nounderline abstract_t">Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011; 124:1765.</a></li><li><a class="nounderline abstract_t">Rajagopalan S, Mohler E 3rd, Lederman RJ, et al. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. Am Heart J 2003; 145:1114.</a></li><li><a class="nounderline abstract_t">Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007; 153:874.</a></li><li><a class="nounderline abstract_t">Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377:1929.</a></li><li><a class="nounderline abstract_t">Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17:683.</a></li><li><a class="nounderline abstract_t">Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007; 115:1234.</a></li><li><a class="nounderline abstract_t">Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16:972.</a></li><li><a class="nounderline abstract_t">Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118:58.</a></li><li><a class="nounderline abstract_t">Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010; 52:1525.</a></li><li><a class="nounderline abstract_t">Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010; 17:1152.</a></li><li><a class="nounderline abstract_t">Anghel A, Taranu G, Seclaman E, et al. Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia. Curr Neurovasc Res 2011; 8:183.</a></li><li><a class="nounderline abstract_t">Mäkinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6:127.</a></li><li><a class="nounderline abstract_t">Horsch S, Claeys L. Epidural spinal cord stimulation in the treatment of severe peripheral arterial occlusive disease. Ann Vasc Surg 1994; 8:468.</a></li><li><a class="nounderline abstract_t">Mingoli A, Sciacca V, Tamorri M, et al. Clinical results of epidural spinal cord electrical stimulation in patients affected with limb-threatening chronic arterial obstructive disease. Angiology 1993; 44:21.</a></li><li><a class="nounderline abstract_t">Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2013; :CD004001.</a></li><li><a class="nounderline abstract_t">Anderson SI, Whatling P, Hudlicka O, et al. Chronic transcutaneous electrical stimulation of calf muscles improves functional capacity without inducing systemic inflammation in claudicants. Eur J Vasc Endovasc Surg 2004; 27:201.</a></li><li><a class="nounderline abstract_t">Ellul C, Formosa C, Gatt A, et al. The Effectiveness of Calf Muscle Electrostimulation on Vascular Perfusion and Walking Capacity in Patients Living With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Int J Low Extrem Wounds 2017; 16:122.</a></li><li><a class="nounderline abstract_t">Tsang GM, Green MA, Crow AJ, et al. Chronic muscle stimulation improves ischaemic muscle performance in patients with peripheral vascular disease. Eur J Vasc Surg 1994; 8:419.</a></li><li><a class="nounderline abstract_t">Abraham P, Mateus V, Bieuzen F, et al. Calf muscle stimulation with the Veinoplus device results in a significant increase in lower limb inflow without generating limb ischemia or pain in patients with peripheral artery disease. J Vasc Surg 2013; 57:714.</a></li><li><a class="nounderline abstract_t">Babber A, Ravikumar R, Onida S, et al. Effect of footplate neuromuscular electrical stimulation on functional and quality-of-life parameters in patients with peripheral artery disease: pilot, and subsequent randomized clinical trial. Br J Surg 2020; 107:355.</a></li><li><a class="nounderline abstract_t">Loubser PG, Cardus D, Pickard LR, McTaggart WG. Effects of unilateral, low-frequency, neuromuscular stimulation on superficial circulation in lower extremities of patients with peripheral vascular disease. Med Instrum 1988; 22:82.</a></li><li><a class="nounderline abstract_t">Besnier F, Sénard JM, Grémeaux V, et al. The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study. Trials 2017; 18:373.</a></li><li><a class="nounderline abstract_t">Delis KT, Nicolaides AN, Wolfe JH, Stansby G. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up. J Vasc Surg 2000; 31:650.</a></li><li><a class="nounderline abstract_t">Delis KT, Nicolaides AN. Effect of intermittent pneumatic compression of foot and calf on walking distance, hemodynamics, and quality of life in patients with arterial claudication: a prospective randomized controlled study with 1-year follow-up. Ann Surg 2005; 241:431.</a></li><li><a class="nounderline abstract_t">Kakkos SK, Geroulakos G, Nicolaides AN. Improvement of the walking ability in intermittent claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot and calf compression: a randomised controlled trial. Eur J Vasc Endovasc Surg 2005; 30:164.</a></li><li><a class="nounderline abstract_t">Afzelius P, Molsted S, Tarnow L. Intermittent vacuum treatment with VacuMed does not improve peripheral artery disease or walking capacity in patients with intermittent claudication. Scand J Clin Lab Invest 2018; 78:456.</a></li><li><a class="nounderline abstract_t">Hageman D, Fokkenrood HJP, van Deursen BAC, et al. Randomized controlled trial of vacuum therapy for intermittent claudication. J Vasc Surg 2020; 71:1692.</a></li><li><a class="nounderline abstract_t">Hoel H, Pettersen EM, Høiseth LØ, et al. A randomized controlled trial of treatment with intermittent negative pressure for intermittent claudication. J Vasc Surg 2021; 73:1750.</a></li><li><a class="nounderline abstract_t">Tei C, Shinsato T, Miyata M, et al. Waon therapy improves peripheral arterial disease. J Am Coll Cardiol 2007; 50:2169.</a></li><li><a class="nounderline abstract_t">Shinsato T, Miyata M, Kubozono T, et al. Waon therapy mobilizes CD34+ cells and improves peripheral arterial disease. J Cardiol 2010; 56:361.</a></li><li><a class="nounderline abstract_t">Thomas KN, van Rij AM, Lucas SJ, Cotter JD. Lower-limb hot-water immersion acutely induces beneficial hemodynamic and cardiovascular responses in peripheral arterial disease and healthy, elderly controls. Am J Physiol Regul Integr Comp Physiol 2017; 312:R281.</a></li><li><a class="nounderline abstract_t">Xu ZH, Jiang Q, Chen DY, et al. Extracorporeal shock wave treatment in nonunions of long bone fractures. Int Orthop 2009; 33:789.</a></li><li><a class="nounderline abstract_t">Dumfarth J, Zimpfer D, Vögele-Kadletz M, et al. Prophylactic low-energy shock wave therapy improves wound healing after vein harvesting for coronary artery bypass graft surgery: a prospective, randomized trial. Ann Thorac Surg 2008; 86:1909.</a></li><li><a class="nounderline abstract_t">Schmid JP, Capoferri M, Wahl A, et al. Cardiac shock wave therapy for chronic refractory angina pectoris. A prospective placebo-controlled randomized trial. Cardiovasc Ther 2013; 31:e1.</a></li><li><a class="nounderline abstract_t">Nishida T, Shimokawa H, Oi K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 2004; 110:3055.</a></li><li><a class="nounderline abstract_t">Fukumoto Y, Ito A, Uwatoku T, et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 2006; 17:63.</a></li><li><a class="nounderline abstract_t">Belcaro G, Cesarone MR, Dugall M, et al. Effects of shock waves on microcirculation, perfusion, and pain management in critical limb ischemia. Angiology 2005; 56:403.</a></li><li><a class="nounderline abstract_t">Tara S, Miyamoto M, Takagi G, et al. Low-energy extracorporeal shock wave therapy improves microcirculation blood flow of ischemic limbs in patients with peripheral arterial disease: pilot study. J Nippon Med Sch 2014; 81:19.</a></li><li><a class="nounderline abstract_t">Serizawa F, Ito K, Kawamura K, et al. Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication. Circ J 2012; 76:1486.</a></li><li><a class="nounderline abstract_t">Ciccone MM, Notarnicola A, Scicchitano P, et al. Shockwave therapy in patients with peripheral artery disease. Adv Ther 2012; 29:698.</a></li><li><a class="nounderline abstract_t">Cayton T, Harwood A, Smith GE, Chetter I. A Systematic Review of Extracorporeal Shockwave Therapy as a Novel Treatment for Intermittent Claudication. Ann Vasc Surg 2016; 35:226.</a></li><li><a class="nounderline abstract_t">Raza A, Harwood A, Totty J, et al. Extracorporeal Shockwave Therapy for Peripheral Arterial Disease: A Review of the Potential Mechanisms of Action. Ann Vasc Surg 2017; 45:294.</a></li></ol></div><div id="topicVersionRevision">Topic 94161 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223489" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574279" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840332" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29425606" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25237048" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral artery disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30791089" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710165" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821089" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873560" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775528" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intermittent claudication: new targets for drug development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21993771" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adjunctive pharmacotherapies for intermittent claudication--NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23069985" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of interleukin 1βinhibition in cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845751" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32666079" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inflammation and cardiovascular diseases: lessons from seminal clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31277561" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35387480" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27437576" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33503349" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of CD47 Blockade on Vascular Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796571" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vitamin E for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930443" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14577656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antioxidants in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173710" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22003000" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427340" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inflammation and Chlamydia pneumoniae infection correlate with the severity of peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18827977" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dark chocolate: consumption for pleasure or therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24531123" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dark chocolate and vascular function in patients with peripheral artery disease: a randomized, controlled cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24990275" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32078436" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cocoa to Improve Walking Performance in Older People With Peripheral Artery Disease: The COCOA-PAD Pilot Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573159" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of Annurca Apple Polyphenols on Intermittent Claudication in Patients With Peripheral Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339899" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The endothelium and its role in regulating vascular tone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24250251" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The vascular endothelium and human diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19376804" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nitric oxide: link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20585108" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21454745" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23710434" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nitrite: A Physiological Store of Nitric Oxide and Modulator of Mitochondrial Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22248502" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nitrate supplementation's improvement of 10-km time-trial performance in trained cyclists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21071588" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dietary nitrate supplementation reduces the O2 cost of walking and running: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661447" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24436354" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : No improvement of repeated-sprint performance with dietary nitrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22526247" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Influence of acute dietary nitrate supplementation on 50 mile time trial performance in well-trained cyclists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22874535" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dietary nitrate does not enhance running performance in elite cross-country skiers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781895" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Beetroot juice supplementation does not improve performance of elite 1500-m runners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6735451" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cold pressor test as a predictor of hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12615687" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35090799" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sodium nitrate supplementation improves blood pressure reactivity in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28974486" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Combined Dietary Nitrate and Exercise Intervention in Peripheral Artery Disease: Protocol Rationale and Design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976553" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Beet the Best?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18508974" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24363302" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22484664" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nitrite therapy is neuroprotective and safe in cardiac arrest survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704094" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3115772" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nonautocatalytic methemoglobin formation by sodium nitrite under aerobic and anaerobic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17915331" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : L-arginine transporters in cardiovascular disease: a novel therapeutic target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16391217" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23859953" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28366306" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592080" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : L-arginine supplementation in peripheral arterial disease: no benefit and possible harm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940638" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Does l-citrulline supplementation improve exercise blood flow in older adults?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174195" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22119244" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633305" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prostanoids for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091595" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prostanoids for critical limb ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28189475" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy and Safety of Alprostadil in Patients with Peripheral Arterial Occlusive Disease Fontaine Stage IV: Results of a Placebo Controlled Randomised Multicentre Trial (ESPECIAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9142008" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858918" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068415" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350216" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616232" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18372433" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A randomized trial of iloprost in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213235" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956486" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16444463" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29318581" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prostanoids for critical limb ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23842829" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23385271" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21195215" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21195215" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27633186" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Liraglutide and semaglutide reduce cardiovascular events in patients with type 2 diabetes and peripheral arterial disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30072400" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820470" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical epidemiology of cardiovascular disease in chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11641313" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24533939" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31707860" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844192" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222135" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Rivaroxaban in Peripheral Artery Disease after Revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32730905" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32052833" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31656821" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Role of lipoprotein (a) in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19234501" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24056686" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27417585" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096845" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25936325" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096834" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586750" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32223446" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31893580" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22819432" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325450" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415628" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22289660" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21586448" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Vascular disease and stem cell therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205941" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22498564" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24438903" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24389220" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Application of adipose-derived stem cells in critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24312447" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Atorvastatin treatment of rats with ischemia-reperfusion injury improves adipose-derived mesenchymal stem cell migration and survival via the SDF-1α/CXCR-4 axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043757" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19526389" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161427" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22490340" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426345" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452987" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cell therapy for peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24247554" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24080099" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: the PROPEL Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087795" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21308868" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19627297" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Bone marrow-derived aldehyde dehydrogenase-bright stem and progenitor cells for ischemic repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28209728" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141087" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25525690" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123483" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28096194" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241713" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19929258" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240264" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240264" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240264" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16936417" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205939" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951607" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21216483" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22453769" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20529449" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25567765" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23329572" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424012" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21594960" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21669864" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Short- to mid-term results using autologous bone-marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22079876" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758736" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526721" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Autologous immuno magnetically selected CD133+ stem cells in the treatment of no-option critical limb ischemia: clinical and contrast enhanced ultrasound assessed results in eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304481" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Autologous bone marrow mononuclear cell implantation therapy is an effective limb salvage strategy for patients with severe peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31113463" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Autologous stem cell therapy for peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24766232" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Gene therapy for peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864908" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509344" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12086757" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537336" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504183" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19784813" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989068" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947297" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796772" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452167" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21621834" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776576" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17309918" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18388929" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559703" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146749" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393508" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21675956" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095313" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7811584" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Epidural spinal cord stimulation in the treatment of severe peripheral arterial occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8424581" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Clinical results of epidural spinal cord electrical stimulation in patients affected with limb-threatening chronic arterial obstructive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450547" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718904" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Chronic transcutaneous electrical stimulation of calf muscles improves functional capacity without inducing systemic inflammation in claudicants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682726" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : The Effectiveness of Calf Muscle Electrostimulation on Vascular Perfusion and Walking Capacity in Patients Living With Type 2 Diabetes Mellitus and Peripheral Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8088392" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Chronic muscle stimulation improves ischaemic muscle performance in patients with peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312939" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Calf muscle stimulation with the Veinoplus device results in a significant increase in lower limb inflow without generating limb ischemia or pain in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912491" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Effect of footplate neuromuscular electrical stimulation on functional and quality-of-life parameters in patients with peripheral artery disease: pilot, and subsequent randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259282" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Effects of unilateral, low-frequency, neuromuscular stimulation on superficial circulation in lower extremities of patients with peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28797281" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753272" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729065" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Effect of intermittent pneumatic compression of foot and calf on walking distance, hemodynamics, and quality of life in patients with arterial claudication: a prospective randomized controlled study with 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15890545" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Improvement of the walking ability in intermittent claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot and calf compression: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30261748" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Intermittent vacuum treatment with VacuMed does not improve peripheral artery disease or walking capacity in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31690523" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Randomized controlled trial of vacuum therapy for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33899743" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : A randomized controlled trial of treatment with intermittent negative pressure for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18036456" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Waon therapy improves peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843662" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Waon therapy mobilizes CD34+ cells and improves peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28003211" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Lower-limb hot-water immersion acutely induces beneficial hemodynamic and cardiovascular responses in peripheral arterial disease and healthy, elderly controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18437381" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Extracorporeal shock wave treatment in nonunions of long bone fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022007" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Prophylactic low-energy shock wave therapy improves wound healing after vein harvesting for coronary artery bypass graft surgery: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22953794" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Cardiac shock wave therapy for chronic refractory angina pectoris. A prospective placebo-controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520304" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374144" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079923" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Effects of shock waves on microcirculation, perfusion, and pain management in critical limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614391" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Low-energy extracorporeal shock wave therapy improves microcirculation blood flow of ischemic limbs in patients with peripheral arterial disease: pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447002" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869515" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Shockwave therapy in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27311948" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : A Systematic Review of Extracorporeal Shockwave Therapy as a Novel Treatment for Intermittent Claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28688873" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Extracorporeal Shockwave Therapy for Peripheral Arterial Disease: A Review of the Potential Mechanisms of Action.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
